Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thompson Medical

This article was originally published in The Tan Sheet

Executive Summary

Launches two products on June 1 -- Hemorid for Women hemorrhoid cream and suppositories and Capzasin-P analgesic cream. Hemorid for Women (.25% phenylephrine HCl) and Capzasin-P (.025% capsaicin) will both be promoted with radio and TV advertising. Thompson Med also is introducing this summer Dexatrim Plus Vitamins, a line extension of the weight loss product containing phenylpropanolamine, and a new formula for its Aqua-Ban premenstrual product containing 50 mg pamabrom. The original formula contained 650 mg ammonia chloride and 200 mg caffeine. Dexatrim Plus Vitamins will be promoted through TV ads, and reformulated Aqua-Ban will have radio and print support

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts